SubscribeRenewCustomer Service
C&T magazine Article Archives C&T Article Archive

Featured Articles:
Organic Cosmetic Standards

Galactoarabinan as a Natural SPF Booster
CT July 2008

Read all about our latest issue--
click here!
REACH Summit: Revisited C&T Reach Summit

TheC&T REACH Summit is back. Learn more about the Success Within REACH!
Cosmetics Xchange

C&T magazine is hosting a new way to identify technologies and solutions for product development! Learn more about the CosmeticsXchange.
REACH Round Table REACH Round Table

Questions about REACH regulation? Ask a regulations expert on our new Q&A site
REACH Round Table
C&T Tech Awards

It is time once again to submit nominations for C&T's International Technology Awards. Nominate someone you know.




View Cart

Issue Date:  November 2007
pg 50

Tech Edge: RNA Interference and Therapeutic Applications


Mindy Goldstein, PhD, The Estée Lauder Companies Inc.; Narendra Vaish, PhD, Nastech Pharmaceutical Company

Editor’s note: Regular columnist Mindy Goldstein, PhD, welcomes this “Tech Edge” contribution from colleague Narendra Vaish, PhD, of Nastech Pharmaceutical Company.

From the column editor: Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a new technology that has recently burst onto the scene and is being heavily pursued for use in pharmaceutics. This technology is a class of 20–25 nucleotide-long, double-stranded RNA molecules that play a variety of roles in biology. RNA interference (RNAi) via siRNAs has generated a great deal of interest in both basic and applied biology given its ability to knockdown—i.e., suppress gene expression—essentially any gene of interest.

An increasing number of large-scale RNAi screens have been designed to identify important genes in various biological pathways. Since disease processes also depend on the activity of multiple genes, it is expected that in some situations, turning off the activity of a gene with an siRNA could produce a therapeutic benefit. In the near future, this technology will probably move into the cosmetic world.

In this column, Narendra Vaish, PhD, from Nastech Pharmaceutical Company, presents an overview of interference RNA and therapeutic applications for this technology. He is a senior scientist at the company and leads an RNAi-applied research group. Vaish has extensive experience in drug discovery, drug development, RNAi and molecular evolution. Before joining Nastech, he worked at Sirna Therapeutics, a wholly owned subsidiary of Merck, where he played a leading role in developing the company’s chemically modified siRNAs. Vaish has authored and co-authored numerous research articles and reviews in the fields of RNAi, molecular evolution and peptide chemistry. He is the co-inventor on more than 80 patent applications. His research interests include dermatology, virology, oncology and inflammation.

—Mindy Goldstein, PhD

For the complete article, click "Purchase This Article."




Copyright © 2008 Allured Publishing | Contact Us | Legal Terms